Skip to main content
. 2023 Jan 16;81(3):224–234. doi: 10.1016/j.jacc.2022.10.030

Figure 3.

Figure 3

Death Rates by Baseline IL-6

Thirty-day rates of death in patients randomized to receive PCSK9 inhibitor or placebo, stratified according to median serum IL-6 levels ≤51.29 pg/mL and >51.29 pg/mL at baseline. IL = interleukin; other abbreviations as in Figure 2.